TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02549898
Drug: Feraheme
Normalized name: Feraheme
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
Study: NCT02549898
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol will be applied to provoke migraine attacks in migraineurs
Study: NCT01848873
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5mg daily
Study: NCT01848873
Drug: amlodipine-FA tablet, low dose group
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg amlodipine combined with 0.4 mg of folic acid, daily.
Study: NCT01848873
Drug: amlodipine-FA tablet ,high dose group
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5mg and folic acid 0.8mg daily
Study: NCT03434951
Drug: Bupivacaine Hydrochloride, Spinal
Normalized name: Bupivacaine Hydrochloride, Spinal
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia
Study: NCT03434951
Drug: Morphine hydrochloride, Spinal
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecally administered morphine 0,2mg (2mg/ml, 0,1ml)
Study: NCT00458328
Drug: Z-338
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00517491
Drug: lanreotide (Autogel formulation)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
Study: NCT00784810
Drug: Oxycodone/Naloxone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
Study: NCT03117738
Drug: AstroStem
Normalized name: AstroStem-V
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
Study: NCT01087853
Drug: Crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 litres intravenous infusion in 60 minutes
Study: NCT01087853
Drug: Colloid
Normalized name: tin colloid
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 litre intravenous infusion over 30 minutes
Study: NCT03077763
Drug: Sodium Nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02085213
Drug: Glyceryl Trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01252342
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
Study: NCT01252342
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
Study: NCT01382199
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04260659
Drug: Dexmedetomidine Hydrochloride [Dexdor]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
Study: NCT04260659
Drug: Ketamine [Ketalar]
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
Study: NCT04260659
Drug: Lidocaine [Xylocaine 2%]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
Study: NCT04260659
Drug: Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
Study: NCT01991938
Drug: VS-5584
Normalized name: VS-5584
DrugBank: VS-5584 (DB12986)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00879606
Drug: ALT-836
Normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
Study: NCT00160576
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05041322
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
Study: NCT04644250
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.
Study: NCT04644250
Drug: Paclitaxel liposome/Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
Study: NCT00251953
Drug: Tesaglitazar
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00251953
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02586987
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib oral
Study: NCT02586987
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab, IV
Study: NCT01617187
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
Study: NCT01617187
Drug: Placebo Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
Study: NCT01617187
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
Study: NCT01617187
Drug: Placebo Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
Study: NCT01575405
Drug: Rectal formulation (RF) of tenofovir 1% gel
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
Study: NCT01575405
Drug: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy) propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
Study: NCT02550314
Drug: fiblast,gelatin sponge,fibrin glue
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00728390
Drug: PF-00299804
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
Study: NCT02268552
Drug: branaplam
Normalized name: Branaplam
DrugBank: Branaplam (DB14918)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03972111
Drug: TPOXX 200Mg Capsule
Normalized name: TPOXX 200mg Capsule
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TPOXX 600 mg (three 200 mg.) capsules twice daily for 14 days
Study: NCT00598429
Drug: Inhaled Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
Study: NCT01945606
Drug: BAY1067197 (treatment 2)
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
Study: NCT02352558
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
Study: NCT02352558
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
Study: NCT02352558
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
Study: NCT02352558
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
Study: NCT00344786
Drug: CNF2024 (BIIB021)
Normalized name: BIIB021
DrugBank: BIIB021 (DB12359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment.
Study: NCT02988973
Drug: roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral administration
Study: NCT02988973
Drug: DA
Normalized name: MDA
DrugBank: Tenamfetamine (DB01509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration
Study: NCT01882322
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01882322
Drug: Advagraf
Normalized name: Astagraf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01640808
Drug: NIK-333(peretinoin)
Normalized name: Viable and metabolically active allogeneic human NIKS keratinocytes and human dermal fibroblasts cellularized layered scaffold
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg (8 x 75mg capsules) orally, twice a day
Study: NCT00325650
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tablet, oral administration
Study: NCT01921673
Drug: Dovitinib and docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used.
Study: NCT01715987
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg, oral daily for two years
Study: NCT01715987
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg oral daily for two years.
Study: NCT00016393
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02652507
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
Study: NCT01381692
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT01381692
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01381692
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02652507
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus dose 2 mg/kg after first set of research images are obtained
Study: NCT02614287
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT00878631
Drug: hypertonic saline mixed with dextran
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
Study: NCT01988246
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
Study: NCT03545893
Drug: OxyCODONE 5 Mg Oral Tablet
Normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
Study: NCT03296852
Drug: Lumason
Normalized name: Lumason
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
Study: NCT00176618
Drug: curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 250 mg po BID
Study: NCT00019240
Drug: cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01577550
Drug: BI 655066 (very high i.v. dose)
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single very high i.v. dose BI 655066
Study: NCT01577550
Drug: BI 655066 (high s.c. dose)
Normalized name: Zinc, bis(diethylcarbamodithioato-S,S')-
DrugBank: Ditiocarb zinc (DB14193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high s.c. dose BI 655066
Study: NCT01577550
Drug: BI 655066 (low i.v. dose)
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single low i.v. dose BI 655066
Study: NCT01577550
Drug: BI 655066 (high medium i.v. dose)
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single high medium i.v. dose BI 655066
Study: NCT01577550
Drug: BI 655066 (very low i.v. dose)
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single very low i.v. dose BI 655066
Study: NCT01577550
Drug: BI 655066 (low s.c. dose)
Normalized name: Zinc, bis(diethylcarbamodithioato-S,S')-
DrugBank: Ditiocarb zinc (DB14193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single low s.c. dose BI 655066
Study: NCT01577550
Drug: BI 655066 (high i.v. dose)
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single high i.v. dose BI 655066
Study: NCT01577550
Drug: BI 655066 (low medium i.v. dose)
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single low medium i.v. dose BI 655066
Study: NCT02460679
Drug: EPI-589
Normalized name: EPI-589
DrugBank: EPI-589 (DB16041)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
Study: NCT00796107
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole was administered orally at a dose 2.5 mg daily.
Study: NCT01572727
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous paclitaxel 80 mg/m2 per week given until progression
Study: NCT00517712
Drug: Single agent arsenic trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: duration of maintenance therapy, 6 months versus 12 months
Study: NCT02166008
Drug: Repamipide
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT02834780
Drug: H3B-6527
Normalized name: H3B-6527
DrugBank: H3B-6527 (DB15169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3B-6527 by mouth once or twice daily at specified doses.
Study: NCT01716312
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
Study: NCT00198562
Drug: Amlodipine, Losartan
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
Study: NCT03071692
Drug: K-877
Normalized name: MK-8776
DrugBank: MK-8776 (DB11899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2mg tablet
Study: NCT02576678
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04597268
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous dexmedetomidine 1 mic/kg
Study: NCT04597268
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine 1mg/kg
Study: NCT04597268
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam 0.05 mg/kg
Study: NCT03651089
Drug: SP16
Normalized name: Sulfapyridine
DrugBank: Sulfapyridine (DB00891)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection of experimental anti-inflammatory drug
Study: NCT00687648
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given as previously prescribed
Study: NCT04022876
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered IV on Day 1 of every 21-day cycle.
Study: NCT04022876
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed administered IV on Day 1 of every 21-day cycle.
Study: NCT04022876
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan administered IV on Days 1-5 of every 21-day cycle.